Cargando…

ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines

Squamous cell carcinoma of the head and neck (HNSCC) is characterized by high morbidity and mortality. Treatment failure, drug resistance and chemoradiation toxicity have necessitated the development of alternative treatment strategies. Styryl benzyl sulfones, a family of novel small molecule inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prasad, Anil, Khudaynazar, Nagina, Tantravahi, Ramana V., Gillum, Amanda M., Hoffman, Benjamin S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346722/ https://www.ncbi.nlm.nih.gov/pubmed/27764820 http://dx.doi.org/10.18632/oncotarget.12692

Ejemplares similares

Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na)
por: Monfort-Vengut, Ana, et al.
Publicado: (2023)

Therapeutic Targeting PLK1 by ON-01910.Na Is Effective in Local Treatment of Retinoblastoma
por: Ma, Huan, et al.
Publicado: (2021)

Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia
por: Baker, Stacey J., et al.
Publicado: (2019)

Rigosertib and Cholangiocarcinoma: A Cell Cycle Affair
por: Malacrida, Alessio, et al.
Publicado: (2021)

Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent
por: Jost, Marco, et al.
Publicado: (2020)

Anti-tumor effects of rigosertib in high-risk neuroblastoma
por: Radke, Katarzyna, et al.
Publicado: (2021)

Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent
por: Malacrida, Alessio, et al.
Publicado: (2023)

Rigosertib inhibits MEK1–ERK pathway and alleviates lipopolysaccharide‐induced sepsis
por: Wang, Yin, et al.
Publicado: (2021)

In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells
por: Malacrida, Alessio, et al.
Publicado: (2021)

Drug screening in human physiologic medium identifies uric acid as an inhibitor of rigosertib efficacy
por: Rawat, Vipin, et al.
Publicado: (2023)

Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest
por: Hyoda, Tomoko, et al.
Publicado: (2015)

Synthesis and antitumor effects of novel benzyl naphthyl sulfoxide/sulfone derivatives derived from Rigosertib
por: Tang, Lin, et al.
Publicado: (2021)

Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent
por: Jost, Marco, et al.
Publicado: (2017)

Rigosertib-Activated JNK1/2 Eliminate Tumor Cells through p66Shc Activation
por: Günther, Julia K., et al.
Publicado: (2020)

Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer
por: Zhou, Xinyi, et al.
Publicado: (2022)

Guggulsterone Targets Smokeless Tobacco Induced PI3K/Akt Pathway in Head and Neck Cancer Cells
por: Macha, Muzafar A., et al.
Publicado: (2011)

Role of PI3K/AKT pathway in squamous cell carcinoma with an especial focus on head and neck cancers
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2022)

Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic “dual-hit” option
por: Dietrich, Peter, et al.
Publicado: (2017)

PI3K/AKT/mTOR Signaling Pathway in HPV-Driven Head and Neck Carcinogenesis: Therapeutic Implications
por: Aguayo, Francisco, et al.
Publicado: (2023)

Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas
por: García-Carracedo, Darío, et al.
Publicado: (2016)

Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell Carcinomas
por: Su, Yu-Chieh, et al.
Publicado: (2022)

Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome
por: Xu, Feng, et al.
Publicado: (2014)

Deguelin Induces Apoptosis by Targeting Both EGFR-Akt and IGF1R-Akt Pathways in Head and Neck Squamous Cell Cancer Cell Lines
por: Baba, Yuh, et al.
Publicado: (2015)

AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity
por: Brolih, Sanja, et al.
Publicado: (2018)

STC2 promotes head and neck squamous cell carcinoma metastasis through modulating the PI3K/AKT/Snail signaling
por: Yang, Shuwen, et al.
Publicado: (2016)

Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma
por: Bernard, Monique, et al.
Publicado: (2020)

ON01210.Na (Ex-RAD(®)) Mitigates Radiation Damage through Activation of the AKT Pathway
por: Kang, Anthony D., et al.
Publicado: (2013)

Profilin 2 Promotes Proliferation and Metastasis of Head and Neck Cancer Cells by Regulating PI3K/AKT/β-Catenin Signaling Pathway
por: Zhou, Kecheng, et al.
Publicado: (2019)

Knockdown of HPIP Inhibits the Proliferation and Invasion of Head-and-Neck Squamous Cell Carcinoma Cells by Regulating PI3K/Akt Signaling Pathway
por: Chen, Yangjing, et al.
Publicado: (2016)

In vitro chemosensitivity of head and neck cancer cell lines
por: Schuler, PJ, et al.
Publicado: (2010)

Metadherin Regulation of Vascular Endothelial Growth Factor Expression Is Dependent Upon the PI3K/Akt Pathway in Squamous Cell Carcinoma of the Head and Neck
por: Zhu, Gang-cai, et al.
Publicado: (2015)

FOXM1 Promotes Head and Neck Squamous Cell Carcinoma via Activation of the Linc-ROR/LMO4/AKT/PI3K Axis
por: Ma, Xiao, et al.
Publicado: (2021)

Co-Targeting the EGFR and PI3K/Akt Pathway to Overcome Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma: What about Autophagy?
por: Zaryouh, Hannah, et al.
Publicado: (2022)

Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck
por: Stegeman, Hanneke, et al.
Publicado: (2012)

AKT3 is a key regulator of head and neck squamous cell carcinoma
por: Takahashi, Hideyuki, et al.
Publicado: (2021)

Head and Neck Cancer
por: Psyrri, Amanda, et al.
Publicado: (2009)

Head and neck oncology: The Indian scenario
por: Shah, Snehal Bhupesh, et al.
Publicado: (2016)

Vascular mimicry in cultured head and neck tumour cell lines
por: Upile, Tahwinder, et al.
Publicado: (2011)

Persistent Head and Neck Cancer Following First-Line Treatment
por: Steinbichler, Teresa Bernadette, et al.
Publicado: (2018)

Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review
por: de Kort, W. W. B., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cam6b7rfb5456urjdcpq7lnr88